Venture Trajectory Presets
Advisory Executive Summary
Evaluating preclinical assay speed and institutional IP exclusivity for Series A venture bankability.
Grounding from Quora Life Science Advisors & Biotech Founders: IP ownership assignment is crucial for academic spinouts; wetlab accelerators provide bridge facilities before institutional Series A.
Estimated Post-Money Valuation
$42,500,000
Stage-risk adjusted asset multiple
Exit / Acquisition Probability
78%
Based on pipeline milestones & trials
Investor Bankability Rating
High (Bankable Series A)
Founder credentials + accelerator vetting
IP Defensibility Score
94%
Exclusive license + composition of matter
Treasury Runway
12.5
Months until subsequent tranche
Risk Profile & Regulatory Barrier
Moderate Regulatory / Strong IP
Trial IND compliance matrix
Clinical & Commercial Progression Runway
Live Milestone Map
18-Month Treasury Cash Exhaustion Trajectory
Zero Cash Threshold